U Niemann C, Munir T, Owen C, Follows G, et al. First-line ibrutinib-venetoclax in chronic lymphocytic leukemia: GLOW 67-month results and grade 3/4 adverse event-free progression-free survival. Leukemia 2026 Oct 2. doi: 10.1038/s41375-026-03150.
PMID: 42827117